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Background: The Head and Neck Cancer Working Group of Swiss Group for Clinical
Cancer Research (SAKK) has investigated the level of consensus (LOC) and discrepancy
in everyday practice of diagnosis and treatment in head and neck cancer.
Materials and Methods: An online survey was iteratively generated with 10 Swiss
university and teaching hospitals. LOC below 50% was defined as no agreement, while
higher LOC were arbitrarily categorized as low (51–74%), moderate (75–84%), and
high (≥85%).
Results: Any LOC was achieved in 62% of topics (n = 60). High, moderate, and low
LOC were found in 18, 20, and 23%, respectively. Regarding Head and Neck Surgery,
Radiation Oncology, Medical Oncology, and biomarkers, LOC was achieved in 50, 57,
83, and 43%, respectively.
Conclusions: Consensus on clinical topics is rather low for surgeons and
radiation oncologists. The questions discussed might highlight discrepancies, stimulate
standardization of practice, and prioritize topics for future clinical research.
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INTRODUCTION
This is the third part of the article “A Review of Controversial
Issues in the Management of Head and Neck Cancer: A Swiss
Multidisciplinary andMulti-Institutional Patterns of Care Study,”
providing the results for the items concerning medical oncology
discipline, each followed by a short discussion if deemed relevant.
The details of the methodology is presented in the first part of
this series.
RESULTS AND DISCUSSION
Medical Oncology
This section contains some overlapping topics with the previous
sections regarding concurrent CRT and induction chemotherapy.
The focus remains on the medical oncologists’ point of view.
Concurrent Chemoradiotherapy
â Cetuximab is preferred in combination with definitive
radiotherapy in loco-regionally advanced HNSCC for cisplatin-
ineligible patients: moderate LOC (80%).
An important question remains which approach is preferred in
cases where cisplatin cannot be applied due to contraindications
or patient related factors precluding its application (age,
performance status, hearing loss etc.). For this situation,
cetuximab (1) as alternative choice is favored in 8/10 centers.
One center prefers carboplatin, whereas in another center a
combination regimen with 5-fluorouracil (5-FU) and mitomycin
C (2, 3) vs. Cetuximab is discussed on patient basis.
Different systemic modalities for concurrent treatment were
investigated during the last decades. Cisplatin given every 3
weeks remains the standard of care (4, 5). A minimal dose of
≥200 mg/m2 cisplatin has to be administered to achieve optimal
outcome (6). Nevertheless, only 61% of patients tolerate the
standard dose of 100 mg/m2 times three (7). Therefore, different
alternatives are investigated. Among them, the well-tolerated
platinum alternative carboplatin, alone, or in combination with
5-FU was the combination used by the GORTEC group (8).
Cetuximab, based on high level evidence (1), was the preferred
choice within our survey, despite the lack of randomized
comparison to cisplatin at the time of the survey. Recently, two
phase III randomized trials showed that cetuximab is associated
with inferior overall survival compared to cisplatin even in the
low and intermediate risk HPV-associated OPSCC (9, 10). For
mitomycin C in combination with 5-FU, one randomized trial
showed superiority of CRT in terms of locoregional control
and survival to a dose escalated hyperfractionated accelerated
radiation therapy schedule without systemic therapy (11, 12). For
mitomycin C, as monotherapy or in combination, no randomized
phase III data is available, in comparison to standard of care
cisplatin or cetuximab.
â No agreement in the radiosensitizer indication in post-
operative setting for cisplatin-ineligible patients: no consensus.
The same question in the adjuvant CRT setting yielded a different
pattern: cetuximab was the preferred choice in 4, carboplatin in 5
centers, In the remaining center, the radiation oncologist would
prefer 5-fluorouracil with mitomycin c, whereas the medical
oncologist would opt for cetuximab, or carboplatin instead.
In the adjuvant setting, no high-level evidence is available for
cetuximab. Despite this fact, almost half the centers adopt the data
from non-operated locally advanced disease (1) and prescribe
cetuximab. Carboplatin is the preferred agent as monotherapy.
For mitomycin C as monotherapy or in combination with
dicumarol, an improvement was shown but not regarding overall
survival (13). For the combination of 5-FU an extrapolation from
the existing data from non-operated locally advanced disease
is assumed.
â The cisplatin regimen in terms of dose and cycle frequency
concomitant with radiotherapy is quite heterogeneous:
no consensus.
Platinum-based regimens are administered weekly in 4/10, every
3 weeks in 5 centers, and every 3 weeks but distributed over 5
days every 3 weeks in 1 center.
Shortly after our survey was completed, data presented at the
annual congress of clinical oncology ASCO 2017 was presented
and later on published, showing superiority of the 3-weeks
application of cisplatin vs. a weekly application (14). Probably,
from the four centers applying cisplatin weekly, some would
consider changing their opinion.
â All centers prefer to continue the treatment with another
systemic agent in patients who cannot complete the planned
number of cycles of cisplatin: high LOC (100%).
If a patient was not able to continue with cisplatin after ≥1
cycle, systemic treatment is switched to another regimen in
10/10 centers. In one center, treatment is switched to 5-FU
and mitomycin c or carboplatin alone. All other centers prefer
cetuximab or carboplatin.
We are not aware of any solid data confirming the benefit of
any switch strategy, and with which combination, if there is any
value at all. Of note, one of the participating centers recently
published a hypothesis-generating retrospective study indicating
a higher incidence in second primary cancers, when cetuximab
was administered after the discontinuation of platinum-based
chemotherapy, compared to pure cetuximab, or platinum-based
therapy (15).
â Age is not considered as a strict factor regarding the
decision whether to administer concomitant chemotherapy:
high LOC (100%).
There was total consensus (10/10) about administering
chemotherapy concomitant with radiotherapy to selected,
medically fit patients even older than 70 years.
Even if there is no randomized prospective data confirming the
efficacy of a concomitant strategy in this patient group, all centers
apply the same regimen as in their younger counterparts. Some
analyses show similar outcomes for these patients despite the
higher age (16). Biological age seems to be of importance more
than chronological age.
â ECE is a well-established high-risk factor for post-operative
concomitant CRT indication: high LOC (100%).
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â In most centers, positive resection margin is considered a high-
risk factor for post-operative concomitant CRT indication: high
LOC (90%).
Risk factors warranting adjuvant concomitant chemotherapy to
radiotherapy vary between centers and are elucidated in Table 1.
Induction Chemotherapy
â The use of induction chemotherapy is not part of the routine:
low LOC (60%).
The use of induction chemotherapy with the intention of
increasing oncological outcome is used in 4/10 centers. The
other centers either never administer induction chemotherapy,
or only do so in rare cases in presence of bulky disease, in
which performing an up-front curative CRT with full-dose is
not realistically applicable or feasible. An exact specification of
the induction regimen was not pointed out [classic TPF regimen
(docetaxel, cisplatin, 5-fluorouracil) (17, 18), adapted TPF, other
combination chemotherapy].
Induction chemotherapy is a controversial topic in HNSCC.
Nevertheless, during the last decade one regimen, applied
“classically” or “adapted” showed level I evidence for having better
survival compared to radiotherapy alone in selected patients
(17, 18). With the standard of care approach of concurrent
radiotherapy and cisplatin, trials comparing these two approaches
were eagerly awaited. From five randomized phase III trials, only
two compared standard concurrent treatment vs. induction with
TPF followed by the same treatment (19, 20). All the other trials
were underpowered or did not reach their recruitment goal.
Moreover, inadequate systemic agents were applied concurrently
to radiotherapy. The trial by Hitt et al. showed a trend toward an
improvement of overall survival, but was formally negative (19).
A trial with an “adapted” TPF regimen also called “Italian” TPF
was able to show a marked and impressive overall survival benefit
of more than 20 months (20). The trial is controversial for its
design, but the main question, whether an induction approach
irrespective of the following concurrent treatment (cisplatin
and 5-FU or cetuximab), defined after a second randomization,
improved outcome was clearly answered. Concerns about a
lower rate of completion of radiotherapy and a higher mortality
rate were raised, but could in part be refuted by recent
trials. Despite these arguments, induction chemotherapy reduces
distant metastases rates more prominently than concurrent CRT
alone (21). In the particular case of locally advanced laryngeal
cancer, value of induction chemotherapy is higher, due to available
data and long-term outcome of pivotal trials, showing better
outcome with higher larynx-preservation rate (22–24).
Whether to administer induction chemotherapy in
nasopharynx cancer or not is an ongoing discussion. The
most recently published study by Sun et al. (25) is a well-
designed and conducted study, whose results indicate a favorable
progression-free survival with the addition of TPF administered
before CRT. However, it is important to note the eligibility
criteria and the patient collective of this study. Only cN+
patients younger than 60 years old were allowed. Moreover, the
distribution of WHO histological subtypes are neither reported
nor mentioned in the published article. Considering the dramatic
geographic differences of the histology, a direct implementation
of the results of a study from China to European and American
patients, especially those with non-EBV tumors, is questionable.
Nevertheless, for those who find the study results convincing
enough to change their practice, the investigators of the same
study created a helpful nomogram based on the trial database to
predict the extent of potential gain via induction chemotherapy
for a given patient (26).
â The use of induction/neoadjuvant chemotherapy for optimal
decision-making in locally advanced laryngeal cancer is
preferred: low LOC (70%).
However, 7/10 centers favor the use of induction/neoadjuvant
(the term “neoadjuvant” is rather used, if a surgery is
planned afterwards) chemotherapy for decisionmaking purposes
concerning larynx preservation (22, 27).
Nasopharyngeal, Nasal, and Paranasal Sinus Tumors
â Administration of chemotherapy before the primary treatment
of sino-nasal tumors is preferred due to various reasons: low
LOC (60%).
For the treatment of clinically aggressive, highly proliferating
nasal cavity and paranasal sinus tumors, induction/neoadjuvant
chemotherapy is considered in 6/10 centers, especially in case
of bulky tumors, and/or presence of symptoms to avoid disease
progression until start of radiotherapy (5/6), further to achieve
clear surgical margins (1/6).
Due to the relatively low incidence and variety of histological
subtypes of nasal cavity and paranasal sinus tumors, there
is no convincing level of evidence for or against the use of
chemotherapy before, during, or after the primary treatment.
TABLE 1 | Depending on the following risk factors the centers administer concurrent chemotherapy together with adjuvant radiotherapy.
Center 1 2 3 4 5 6 7 8 9 10
Number of pos. lymph nodes X X X X X
Extracapsular spread X X X X X X X X X X
Vascular embolism X
Perineural disease X X
Positive resection margins X X X X X X X X X
Stage III-IVB disease X
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Nevertheless, it is interesting to see a low but presence LOC
among participating centers.
â Concomitant CRT is preferred for the treatment of sino-nasal
tumors: moderate LOC (70%).
For the treatment of loco-regionally advanced nasal and
paranasal sinus tumors, concurrent chemotherapy is regularly
administered in 7/10 centers. In 2 centers, it is administered only
in selected cases based on tumor board discussion. One center
never performs radiotherapy with concomitant chemotherapy.
There is moderate consensus, that locally advanced disease needs
multimodality treatment. This according to almost all guidelines
available (NCCN, ESMO, etc.). One center seems to diverge from
this approach, probably due to toxicity concerns.
â Concerning the indication of adjuvant chemotherapy for
nasopharynx cancer, no standard approach was observed:
no consensus.
Among participating centers, adjuvant chemotherapy for
nasopharynx cancer is omitted in three out of ten centers;
performed in all cases in three centers; in selected cases at
four centers. However, when asked, the definition of “selected
cases” was not further specified in three centers. In one center
selection was based on treatment response and EBV titer
if applicable.
Treatment of nasopharyngeal cancer is a field of controversy.
Stages > I need multimodality treatment, where CRT is
established as the standard of care (28, 29). Further adjuvant
chemotherapy, traditionally proposed for years is based on a
pivotal Intergroup 0099 study (30), which had its caveats, raising
concerns about the quality of the radiotherapy in the trial and
highlighting the importance of patient selection. Despite the
co-existence of negative trials showing the futility of adjuvant
chemotherapy after radiotherapy alone (31, 32) or CRT (33, 34),
an added benefit of adjuvant treatment was confirmed by meta-
analyses, one published in 2015 of 19 trials with a total of
4,806 patients, showing the most favorable overall survival (HR
0.65; 95% CI, 0.56–0.76) compared to CRT without adjuvant
chemotherapy (HR, 0.80; 95% CI, 0.70–0.93) (35). The other
meta-analysis including 20 trials and 5,144 patients, showed that
the addition of adjuvant chemotherapy to CRT was associated
with better PFS compared to CRT only (HR 0.81; 95% CI, 0.66–
0.98) (36). On the other hand, the most recently published phase
III trial showed no benefit of adjuvant chemotherapy when added
to CRT, even though the study only included high-risk patients
with detectable post-CRT plasma EBV DNA (37). Moreover,
a majority of patients do not tolerate full adjuvant treatment.
Therefore, induction treatment was studied within phase III trials
and showed differing results. Nevertheless, two phase 3 trials
(25, 38) and a meta-analysis (36) were positive for the primary
endpoint overall survival.
Supportive Measures and Oligometastatic Disease
â Prophylactic use of colony stimulating factors is not preferred
during CRT: moderate LOC (80%).
In 2/10 centers, prophylactic use of colony-stimulating factors
during CRT was reported.
Cautious application of colony-stimulating factors is probably
due to reports finding adverse outcome during chemo-radiation
(39) and pre-clinical data suggesting tumor proliferation (40)
with such agents. Additionally, the efforts of reducing treatment-
related mucositis were futile (41, 42). Although not belonging
to the same category of agents, it is also worth to note
that the use of erythropoiesis-stimulating agents to overcome
anemia and hypoxia was shown to cause an unexpected negative
outcome (43).
â Induction/neoadjuvant chemotherapy for subsequent
decision-making is preferred in oligometastatic HNSCC:
low LOC (60%).
For the treatment of oligometastatic (defined as up to 3
metastases) cases at the initial diagnosis, 6/10 centers consider
administering induction/neoadjuvant chemotherapy, and decide
thereafter based on response the final treatment concept (curative
vs. palliative). Three centers never pursue this strategy. One
center directly treats the locoregional and distant disease with
curative intent.
Compared to other tumor entities (e.g., breast, colorectal,
prostate, non-small lung cancer, malignant melanoma),
the concept of oligometastatic disease and its treatment in
HNSCC were not extensively investigated. Retrospective series
demonstrate 5-years survival rates of 20% and higher after
local ablation by means of surgery or SBRT of oligometastatic
disease (44, 45). However, a high level of evidence is still lacking.
Moreover, the optimal strategy for the synchronous presentation
of the oligometastases at the time of initial diagnosis poses a
more specific question, which still remains unanswered. The
heterogeneity in the patterns of treatment among our 10 centers
seems to reflect this ambiguity.
Systemic Treatments for Recurrent/Metastatic Disease
â In first line, EXTREME is the preferred systemic treatment
regimen for recurrent/metastatic disease (R/M): low
LOC (60%).
â The use of 2nd line anti-PD1 checkpoint inhibitors are
preferred in anti-EGFR pre-treated and not pre-treated R/M:
moderate LOC (70–80%, respectively).
â Anti-EGFR pre-treated patients would be encouraged to
participate in clinical trials for ≥2nd line treatment: low
LOC (60%).
â Anti-EGFR-naïve patients are considered for anti-EGFR
treatment as ≥2nd line: low LOC (60%).
The EXTREME regimen containing a platinum compound with
5-fluorouracil and cetuximab is considered for patients with
R/M and an ECOG performance status 0–2 in 6/10 centers.
The remaining four centers do not necessarily consider systemic
treatment according to the pivotal EXTREME trial especially for
patients with higher ECOG performance status (46). Second-
line systemic treatment choice was mostly based on whether or
not previous treatment contained cetuximab (Table 2). There
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TABLE 2 | Preferred second-line systemic treatments depending on previous anti-EGFR application.
Center 1 2 3 4 5 6 7 8 9 10
ANTI-EGFR PRE-TREATED
Methotrexate X X X
Cetuximab X
Taxane C M M
Anti-PD1 antibody* X X X X X X X
Clinical trial X X X X X X
Best supportive care X X X
ANTI-EGFR-NAÏVE
Methotrexate X X
Anti-EGFR antibody X X X X X X
Taxane C M
Anti-PD1 antibody* X X X X X X X X
Clinical trial X X X X
Best supportive care X
*We reassessed second-line treatment choice after approval of novel anti-PD-1 checkpoint inhibitors. These agents were given under the category “compassionate use.” C, combination;
M, monotherapy.
was a moderate LOC (70–80%) among the centers about the
application of nivolumab in this setting (47). Nevertheless, the
general heterogeneity in the R/M setting among participating
centers is not to be overlooked.
CONCLUSION
The findings of our survey indicate a low LOC among head
and neck oncologists working in academic and multidisciplinary
setting in 10 Swiss institutions. Regarding the results and
the discussion concerning the specialties other than medical
oncology, the reader is advised to read the corresponding parts
of this article. The highest LOC was achieved among medical
oncologists, whereas the lowest was observed among head and
neck surgeons. On the other hand, this level of disagreement
may also depend on the topics chosen for the survey, and
not necessarily the heterogeneity within the disciplines. It is
also interesting to witness a low LOC regarding topics, where
a high level of evidence actually does exist, and vice versa.
This article is expected to serve the head and neck oncologists
to be aware of their discrepancies and to stimulate discussion
toward standardization of practice and prioritize topics of future
clinical research.
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